Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era

This publication has 33 references indexed in Scilit:

• Task force 6. Cost effectiveness of assessment and management of risk factors
  Journal of the American College of Cardiology, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• The Cost-effectiveness of HMG-CoA Reductase Inhibitors to Prevent Coronary Heart Disease
  Published by American Medical Association (AMA) ,1995
• Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
  JAMA, 1993
• The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
  Archives of internal medicine (1960), 1993
• Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart Disease
  Published by American Medical Association (AMA) ,1991
• Reducing High Blood Cholesterol Level With Drugs
  Published by American Medical Association (AMA) ,1990
• Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The Netherlands
  The American Journal of Cardiology, 1990
• Cutting Into Cholesterol
  JAMA, 1988
• The Lipid Research Clinics Coronary Primary Prevention Trial Results
  JAMA, 1984